/
Metabolic & Endocrine
Type 2 Diabetes
194
Pipeline Programs↗
502
Active Trials↗
210
Companies Involved↗
Type 2 Diabetes is a highly competitive landscape with 194 programs across 210 companies. The most active players are Novo Nordisk, Eli Lilly, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. 46 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical120
Phase 111
Phase 217
Phase 346
Approved
No programs
Analysis
Modality Breakdown
97%
Small molecule
173 of 178 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 178 classified programs, each share of the total. Modality classified for 94% of 194 pipeline programs.
Analysis
Trial Status
3,201
clinical trials
Completed2,240 · 70%
Recruiting221 · 7%
Unknown status202 · 6%
Terminated184 · 6%
Not yet recruiting148 · 5%
Active, not recruiting111 · 3%
Other95 · 3%
Clinical Trials
Trial Activity
3201 trials
Page 1 of 214
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)